Literature DB >> 10871731

Non-infectious lung complications are closely associated with chronic graft-versus-host disease: a single center study of incidence, risk factors and outcome.

C Duncker1, D Dohr, S Harsdorf, J Duyster, M Stefanic, C Martini, M Treiber, B Hertenstein, J Novotny, R Arnold, H Heimpel, L Bergmann, D Bunjes.   

Abstract

Non-infectious lung complications (NILC) are frequent, influencing morbidity and mortality of patients after allogeneic BMT. Although the term NILC encompasses a number of different entities, an association with GVHD has been noted for almost all of them. Our study was directed towards assessing the incidence and risk factors for developing NILC, as well as the response to treatment and long-term outcome. Forty (14.7%) out of 272 patients surviving for more than 3 months after allogeneic BMT, developed lung complications fulfilling the criteria for NILC. The evaluation was based on clinical investigation, radiologic imaging, lung function tests, broncho-alveolar lavage and biopsies. Risk factors were assessed by univariate and multiple statistical regression models, where chronic GVHD proved to be the only significant risk factor for the development of NILC (P = 0.011). In three patients NILC developed in direct association with donor lymphocyte infusions. The majority of patients responded well to treatment with corticosteroids and immunosuppressive drugs. NILC had no adverse effect on survival. The frequency of NILC was low in autologous (5%) as compared with allogeneic transplants (14.7%) but this difference was not statistically significant. Bone Marrow Transplantation (2000) 25, 1263-1268.

Entities:  

Mesh:

Year:  2000        PMID: 10871731     DOI: 10.1038/sj.bmt.1702429

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  12 in total

1.  Genetic variation in bactericidal/permeability-increasing protein influences the risk of developing rapid airflow decline after hematopoietic cell transplantation.

Authors:  Jason W Chien; Lue Ping Zhao; John A Hansen; Wen Hong Fan; Tanyalak Parimon; Joan G Clark
Journal:  Blood       Date:  2005-11-22       Impact factor: 22.113

2.  Pulmonary symptoms measured by the national institutes of health lung score predict overall survival, nonrelapse mortality, and patient-reported outcomes in chronic graft-versus-host disease.

Authors:  Jeanne Palmer; Kirsten Williams; Yoshihiro Inamoto; Xiaoyu Chai; Paul J Martin; Linus Santo Tomas; Corey Cutler; Daniel Weisdorf; Brenda F Kurland; Paul A Carpenter; Joseph Pidala; Steven Z Pavletic; William Wood; David Jacobsohn; Sally Arai; Mukta Arora; Madan Jagasia; Georgia B Vogelsang; Stephanie J Lee
Journal:  Biol Blood Marrow Transplant       Date:  2013-12-04       Impact factor: 5.742

3.  Results of quantitative chest-CT in chronic pulmonary graft-vs.-host disease (cGvHD) 3 years after allogeneic stem cell transplantation.

Authors:  Christopher Kloth; Wolfgang M Thaiss; Jürgen Hetzel; Georg Bier; Stefan Wirths; Konstantin Nikolaou; Marius Horger
Journal:  J Thorac Dis       Date:  2017-08       Impact factor: 2.895

4.  Chronic GVHD and pretransplantation abnormalities in pulmonary function are the main determinants predicting worsening pulmonary function in long-term survivors after stem cell transplantation.

Authors:  Bipin N Savani; Aldemar Montero; Ramaprasad Srinivasan; Anurag Singh; Aarthi Shenoy; Stephan Mielke; Katayoun Rezvani; Shervin Karimpour; Richard Childs; A John Barrett
Journal:  Biol Blood Marrow Transplant       Date:  2006-12       Impact factor: 5.742

Review 5.  Genetics of allogeneic hematopoietic cell transplantation. Role of HLA matching, functional variation in immune response genes.

Authors:  John A Hansen; Effie W Petersdorf; Ming-Tseh Lin; Steven Wang; Jason W Chien; Barry Storer; Paul J Martin
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

6.  Leukemic infiltration of the lung following allogeneic hematopoietic stem cell transplantation.

Authors:  Kazuhiko Kakihana; Kazuteru Ohashi; Fumikazu Sakai; Noriko Kamata; Yukio Hosomi; Mina Nishiwaki; Reiko Yokoyama; Takeshi Kobayashi; Takuya Yamashita; Hideki Akiyama; Hisashi Sakamaki
Journal:  Int J Hematol       Date:  2008-12-18       Impact factor: 2.490

Review 7.  Bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation-an increasingly recognized manifestation of chronic graft-versus-host disease.

Authors:  Jason W Chien; Steven Duncan; Kirsten M Williams; Steven Z Pavletic
Journal:  Biol Blood Marrow Transplant       Date:  2009-11-05       Impact factor: 5.742

8.  Stable long-term pulmonary function after fludarabine, antithymocyte globulin and i.v. BU for reduced-intensity conditioning allogeneic SCT.

Authors:  S Dirou; F Malard; A Chambellan; P Chevallier; P Germaud; T Guillaume; J Delaunay; P Moreau; B Delasalle; P Lemarchand; M Mohty
Journal:  Bone Marrow Transplant       Date:  2014-02-17       Impact factor: 5.483

Review 9.  Non-infectious pulmonary complications after bone marrow transplantation.

Authors:  I Khurshid; L C Anderson
Journal:  Postgrad Med J       Date:  2002-05       Impact factor: 2.401

10.  Living-donor lobar lung transplantation for broncho-bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation: does bronchiolitis obliterans recur in transplanted lungs?

Authors:  Hirokazu Okumura; Shigeki Ohtake; Yasuo Ontachi; Jun Ozaki; Shigeru Shimadoi; Yuko Waseda; Yukio Kondo; Hirohito Yamazaki; Akiyoshi Takami; Masahide Yasui; Hiroshi Date; Shinji Nakao
Journal:  Int J Hematol       Date:  2007-11       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.